NCT04626947: Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD). |
|
|
| Terminated | 4 | 19 | US | Bezlotoxumab | David Binion, MD, Merck Sharp & Dohme LLC | Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease, C. Diff. Infections | 04/24 | 05/24 | | |
NCT00692939: Autologous Stem Cell Transplantation for Crohn's Disease |
|
|
| Recruiting | 1/2 | 20 | US | autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, Campath-1H, ATG, Anti-thymocyte globulin, rabbit; Thymoglobulin, Melphalan, L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, Thiotepa, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, G-CSF, Neupogen, Granix, Zarxio, Filgrastim, Mesna | Paul Szabolcs | Crohn's Disease | 12/25 | 12/26 | | |
